USPTO

Split?

Reuters reports that the panel hearing the CRISPR gene editing patent case appears split.

The Broad Institute also announced announced a setback in proceedings over a CRISPR patent application filed in Europe.

Michelle Lee, the director of the United States Patent and Trademark Office, has resigned, IP Watchdog reports.

The University of California is appealing the recent CRISPR/Cas9 patent decision.

The Broad Institute has a shot to end the dispute by early 2017 but the more likely outcome is that the parties will argue over whether to fracture the CRISPR IP estate.

Continuing litigation that began in 2012, Illumina alleges that Qiagen's GeneReader infringes on a patent it holds related to sequencing-by-synthesis technology.

The First Call

The parties involved in the CRISPR patent fight recently held a conference call, Stat News reports.

A patent examiner has issued an Initial Interference Memo in the CRISPR patent fight, possibly leading to an interference proceeding, according to the Law and Biosciences Blog.

The report, which takes a look at patent issues as it relates to confirmatory genetic tests, acknowledged that federal legislation has dramatically changed the landscape in recent years.

Piece of the Patents

Researchers report in PLOS One on their examination of the percentage of women represented on patent filings.

Pages

Lawmakers have asked four direct-to-consumer genetic testing companies to explain their privacy policies and security measures, according to Stat News.

The Trump Administration has proposed a plan to reorganize the federal government, the Washington Post reports.

In Science this week: genetic overlap among many psychiatric disorders, and more.

The Economist writes that an increasing number of scientific journals don't do peer review.